Federal regulators announced Thursday that Teva Pharmaceuticals will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.
Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office...
ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone...
The California Supreme Court ruled that settlement agreements between pharmaceutical companies...
Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets.
Teva announced a voluntary recall of eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter.
The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole).
Mylan made an unsolicited $28.9 billion offer to buy the Irish drugmaker last week, but Perrigo’s board of directors unanimously rejected the proposal, saying that the merger substantially undervalues the company and its future growth prospects.
Eagle Pharmaceuticals, Inc. today announced a patent for the use of bendamustine for treating patients requiring restricted fluid and/or sodium intake.
Teva announces the launch of the generic equivalent to Exforge (amlodipine and valsartan) Tablets in four different strengths, in the United States.
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.
Teva Pharmaceutical Industries today announced that it has signed an agreement to sell its Sellersville, Pennsylvania facility to G&W Laboratories, Inc. This sale supports its plans to streamline operations by reducing excess manufacturing capacity and is part of the company’s previously announced cost reduction program.
Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-release (ER) tablets formulated with Teva’s proprietary abuse deterrence technology (CEP-33237).
A consumer safety group is calling on the U.S Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of liver damage.
Teva Pharmaceutical has announced the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States.
The Supreme Court (SCOTUS) decision that a federals appeals court wrongly overturned Teva Pharmaceutical's (Teva) Copaxone patent is a positive credit development for the drug maker, according to Fitch Ratings.
The U.S. Supreme Court on Tuesday sided with Teva Pharmaceutical in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone.
OncoGenex Pharmaceuticals has executed an initial agreement with Teva Pharmaceutical Industries to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers.
Teva Pharmaceutical has announced that the FDA has approved GRANIX® Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe GRANIX for either in-office or at home use.
Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.
The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
Teva has identified 14 pipeline projects for discontinuation or divestment. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017. These cost savings will be directed, in part, to increasing resources in Teva's core therapeutic areas, while another part of which will support the company's efficiency objective.
Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.
Teva Pharmaceutical announced that a positive judgment has been given by the UK High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART ( S ingle inhaler M aintenance A nd R eliever T herapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort®.
The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.
Arena Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited.
Teva Pharmaceutical Industries today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT ® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs).
Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones. Potential peak sales for LBR-101 are estimated to reach $2 to $3 billion.
- Page 1